Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer

e12016 Background: Breast conserving surgery (BCS) is the preferred surgical management for most early-stage breast cancer, given the equivalent survival after BCS plus radiation and mastectomy (M). Clinical reports of an increasing trend in mastectomy from some institutional reviews have been published. The aim of this study was to assess correlation of type of surgery with different factors in our cancer registry database. Methods: We retrospectively reviewed the cancer registry data at UTMC for early breast cancer stage I/II from 2006-2010. Patient demographics, tumor characteristics, institution of surgery, academic versus private surgeon were identified and compared. We used univariate analysis to select factors for entry into a multivariate analysis. Multinomial logistic regression analysis was performed to predict the type of surgery (cancer side mastectomy (CSM) versus BCS, bilateral mastectomy (BM) versus BCS based on the above variables. A p-value of < 0.05 was significant and comparisons were two tailed. Results: We identified 506 eligible patients with stage I/II breast cancer. 306(60.5%) had undergone breast conservative surgery (BCS), 91 (18%) patients had cancer side mastectomy (CSM) and 109 (21.5%) patients had bilateral mastectomy (BM). 298 (59%) patients were stage I and 208 (41%) had stage II, 218 (42%) had undergone surgery at academic center versus 298 (58%) at nonacademic institution. Predictors o CSM were stage II (p =0.0193), high-grade tumor (p=0.015), surgeon from academic institution (p=0.64), age (p=0.61). Predictors of BM were surgeon from academic institution (p=0.060), age (p=0.07). Conclusions: This study confirms some known factors like stage, surgeon expertise, as influencing factors in type of local surgery, while at the same time did not show impact of race and other tumor characteristics. Further research of these factors need to confirm the influence on decision making prospectively.

Download Full-text

A population-based study of ethnicity and breast cancer stage at diagnosis in Ontario

Current Oncology ◽

10.3747/co.22.2359 ◽

2015 ◽

Vol 22 (2) ◽

pp. 97 ◽

Cited By ~ 14

Author(s):

O.M. Ginsburg ◽

H.D. Fischer ◽

B.R. Shah ◽

L. Lipscombe ◽

L. Fu ◽

...

Keyword(s):

Breast Cancer ◽

General Population ◽

South Asian ◽

Chinese Women ◽

Stage I ◽

Stage Ii ◽

Asian Women ◽

Cancer Stage ◽

Stage At Diagnosis ◽

South Asian Women

BackgroundBreast cancer stage at diagnosis is an important predictor of survival. Our goal was to compare breast cancer stage at diagnosis (by American Joint Committee on Cancer criteria) in Chinese and South Asian women with stage at diagnosis in the remaining general population in Ontario.MethodsWe used the Ontario population-based cancer registry to identify all women diagnosed with breast cancer during 2005–2010, and we applied a validated surname algorithm to identify South Asian and Chinese women. We used logistic regression to compare, for Chinese or South Asian women and for the remaining general population, the frequency of diagnoses at stage ii compared with stage i and stages ii–iv compared with stage i.ResultsThe registry search identified 1304 Chinese women, 705 South Asian women, and 39,287 women in the remaining general population. The Chinese and South Asian populations were younger than the remaining population (mean: 54, 57, and 61 years respectively). Adjusted for age, South Asian women were more often diagnosed with breast cancer at stage ii than at stage i [odds ratio (or): 1.28; 95% confidence interval (ci): 1.08 to 1.51] or at stages ii-iv than at stage i (or: 1.27; 95% ci: 1.08 to 1.48); Chinese women were less likely to be diagnosed at stage ii than at stage i (or: 0.82; 95% ci: 0.72 to 0.92) or at stages ii-iv than at stage i (or: 0.73; 95% ci: 0.65 to 0.82).ConclusionsBreast cancers were diagnosed at a later stage in South Asian women and at an earlier stage in Chinese women than in the remaining population. A more detailed analysis of ethnocultural factors influencing breast screening uptake, retention, and care-seeking behavior might be needed to help inform and evaluate tailored health promotion activities.

Download Full-text

P258 Prognostic value of tumor biology and adjuvant systemic therapy in breast cancer stage I

The Breast ◽

10.1016/s0960-9776(15)70290-0 ◽

2015 ◽

Vol 24 ◽

pp. S115

Author(s):

I.V. Kolyadina ◽

I.V. Poddubnaya ◽

G.A. Frank ◽

A.I. Karseladze ◽

D.V. Komov

Keyword(s):

Breast Cancer ◽

Systemic Therapy ◽

Prognostic Value ◽

Tumor Biology ◽

Stage I ◽

Adjuvant Systemic Therapy ◽

Cancer Stage

Download Full-text

Four versus six cycles of docetaxel and cyclophosphamide in early breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e12047 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e12047-e12047

Author(s):

Aparna Basu ◽

Vrushali S. Dabak ◽

Randa Loutfi ◽

Haythem Y. Ali ◽

Hadi Mohammed ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Adverse Events ◽

Early Breast Cancer ◽

Tnm Staging ◽

Stage I ◽

Stage Ii ◽

Limited Series ◽

Grade 3 ◽

Number Of Cycles

e12047 Background: ABC trials established the use of non-anthracycline containing regimen, docetaxel and cyclophosphamide (TC) as adjuvant therapy in early breast cancer. In clinical practice, TC is commonly used in Stage I Triple Negative (TN) and Stage I,II Hormone positive breast cancer. However, no specific recommendations exist in literature, regarding the number of cycles that can be used. i.e. TC4 vs TC6. Our aim, was to determine if TC4 is non-inferior to TC6 when used as adjuvant therapy in early breast cancer. Methods: We retrospectively reviewed 143 patients who were diagnosed with early breast cancer, between 2007 to 2017, at our institution who had received either TC4 or TC6 as adjuvant therapy. The number of cycles the patients received were based on provider preference. The two groups (TC4, TC6) were compared in regard to stage of cancer at diagnosis based on AJCC 7th edition-stratified by TNM staging for hormone positive and T staging only for TN, grade of adverse events, recurrence and death from breast cancer. Median follow up was 5 years. Results: Out of the 143, 102(71.3%) received TC4 and 41(28.7%) received TC6. Among the hormone positive, 42 were stage I and out of which 32(76.2%) received TC4 and 10(23.8%) received TC6 and there were 24 stage II patients, out of which 17(70.8%) received TC4 and 7(29.2%) received TC6. Among the TN group, there were 64 who were T1, out of which 45(70.3%) received TC4 and 19(29.7%) received TC6, while there were 12 T2 patients, out of which 7(58.3%) received TC4 and 5(41.7%) received TC6. Recurrence of breast cancer was seen in 5(4.9%) in TC4 and 3(7.3%) in TC6, p=0.569. Death due to breast cancer was seen in 2(1.9%) in TC4 and 1(2.4%) in TC6, p=0.856. Adverse events were seen in 86(84.3%) in TC4 and 39(95.1%) in TC6,p=0.078. Adverse events of Grade 3 or higher were seen in 10(9.8%) in TC4 and 11(26.8%) in TC6, p=0.09. Conclusions: In this limited series, TC4 appears to be equally effective to TC6, with fewer adverse events of any grade and lower incidence of Grade 3 or higher side effects which was statistically significant. Although the proportion of patients who received TC 4 were higher in our series, the percentage of patients who received TC6 was higher in stage II for hormone positive and T2 for TN when compared to Stage 1 and T1 respectively. We also found a higher percentage of recurrence and death due to breast cancer in TC6 which was not statistically significant and this likely a reflection of the fact that as mentioned above patient with a higher stage at diagnosis tended to receive 6 cycles as compared to 4 cycles and therefore had a higher chance of recurrence in the future.

Download Full-text

After Surgery for Breast Cancer: Which Mode of Surveillance?

Journal of the Royal Society of Medicine ◽

10.1177/014107688908201212 ◽

1989 ◽

Vol 82 (12) ◽

pp. 737-738 ◽

Cited By ~ 5

Author(s):

J J T Tate ◽

P C Clifford ◽

G T Royle ◽

R B Buchanan ◽

I Taylor

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Recurrent Disease ◽

Recurrent Breast Cancer ◽

Stage I ◽

Cancer Stage ◽

Breast Clinic ◽

Asymptomatic Patients ◽

Recurrent Breast

Five hundred and ten women attending a specialized breast clinic for follow-up after surgery of early breast cancer (Stage I and II) have been studied. Recurrence was found most often (58%) in symptomatic women who returned to the clinic earlier than planned. Only 3% of asymptomatic patients had recurrent disease. It is concluded that counselling in symptoms of recurrent breast cancer would allow more efficient follow-up.

Download Full-text

16. The role of radiotherapy in early breast cancer (stage I). A West Midlands Breast Group prospective randomized collaborative study (BR 3002).

The Breast ◽

10.1016/0960-9776(95)90108-6 ◽

1995 ◽

Vol 4 (3) ◽

pp. 231-232 ◽

Cited By ~ 9

Author(s):

D. Spooner ◽

J.M. Morrison ◽

G.D. Oates ◽

D.J. Ellis ◽

M.J.R. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Collaborative Study ◽

Stage I ◽

Cancer Stage ◽

West Midlands ◽

Breast Group

Download Full-text

Identification of biomarkers and functional modules from genomic data in stage-wise breast cancer

Current Bioinformatics ◽

10.2174/1574893615999200922123104 ◽

2020 ◽

Vol 15 ◽

Author(s):

Athira K ◽

Vrinda C ◽

Sunil Kumar P V ◽

Gopakumar G

Keyword(s):

Breast Cancer ◽

Expression Patterns ◽

Differential Expression Analysis ◽

Predictive Biomarkers ◽

Stage I ◽

Stage Ii ◽

Stage Iii ◽

Functional Modules ◽

Incidence And Mortality ◽

Multiple Stages

Background: Breast cancer is the most common cancer in women across the world, with high incidence and mortality rates. Being a heterogeneous disease, gene expression profiling based analysis plays a significant role in understanding breast cancer. Since expression patterns of patients belonging to the same stage of breast cancer vary considerably, an integrated stage-wise analysis involving multiple samples is expected to give more comprehensive results and understanding of breast cancer. Objective: The objective of this study is to detect functionally significant modules from gene co-expression network of cancerous tissues and to extract prognostic genes related to multiple stages of breast cancer. Methods: To achieve this, a multiplex framework is modelled to map the multiple stages of breast cancer, which is followed by a modularity optimization method to identify functional modules from it. These functional modules are found to enrich many Gene Ontology terms significantly that are associated with cancer. Result and Discussion: predictive biomarkers are identified based on differential expression analysis of multiple stages of breast cancer. Conclusion: Our analysis identified 13 stage-I specific genes, 12 stage-II specific genes, and 42 stage-III specific genes that are significantly regulated and could be promising targets of breast cancer therapy. That apart, we could identify 29, 18 and 26 lncRNAs specific to stage I, stage II and stage III respectively.

Download Full-text